Olga Danilchanka

Olga Danilchanka's work experience begins with their role as a Postdoctoral Fellow at The University of Alabama at Birmingham, where they co-authored five articles and received a Senior Research Training Fellowship from the American Lung Association. Olga then moved on to Harvard Medical School as a Postdoctoral Fellow, where they co-authored seven articles, including publications in prestigious journals such as Nature, Cell, and Science Translational Medicine. During this time, they were awarded an NIH Ruth L Kirschstein National Research Service Award Individual Postdoctoral Fellowship.

After their time at Harvard Medical School, Olga joined Evelo Biosciences as a Senior Scientist. Olga worked in this role for a year before transitioning to Merck, where they became a Founding Member and Principal Scientist in the Exploratory Science Center. In this position, they played a key role in developing and implementing the R&D strategy for microbiome discovery, covering infectious diseases and immuno-oncology indications.

Olga then advanced within Merck, taking on the role of Senior Associate in the MRL Ventures Fund and later becoming a Principal. Olga currently holds the position of Principal at the MRL Ventures Fund.

In addition to their roles at Merck, Olga has served as a Board Observer for several companies, including EyeBio, Caraway Therapeutics, Inc., Therini Bio, Inc., and PAQ Therapeutics. Olga has also served as a Board Director for Therini Bio, Inc. and as a Board Observer for Ambagon Therapeutics.

Overall, Olga Danilchanka has an extensive and impressive work experience, with notable accomplishments and contributions to the field of biomedical research and innovation.

Olga Danilchanka pursued their education diligently, starting with their studies at Belarusian State University from 1999 to 2004. Although the specific degree and field of study are not known, their dedication to learning was evident during this period. Following this, they attended the University of Alabama at Birmingham from 2004 to 2010, where they successfully completed their Doctor of Philosophy (Ph.D.) in an undisclosed field of study.